PF 5230907

Drug Profile

PF 5230907

Alternative Names: Factor Xa variant (IL16); FXa; FXaI16L; PF 907; PF-05230907; PF-5230907

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cerebral haemorrhage

Most Recent Events

  • 03 Dec 2016 Adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Cerebral haemorrhage (In volunteers) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Nov 2016 Phase-I clinical trials in Cerebral haemorrhage in United Kingdom, Spain, Canada, USA (IV, Injection) (NCT02687191)
  • 01 Mar 2016 Pfizer completes a phase I trial in Cerebral haemorrhage (In volunteers) in USA (IV) (NCT02537002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top